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I Summary 
Currently, the data sources available suggest that overall methamphetamine availability and 
use in Europe remains relatively low, in comparison with other stimulant drugs. However, 
when viewed collectively, the data suggest that threats in this area appear to be growing 
to a point at which they cannot be ignored. Wastewater analysis and other epidemiological 
data sources suggest some recent methamphetamine diffusion to new markets, with the 
drug now appearing in some southern European countries and becoming more prominent 
in parts of central Europe. There is also evidence of large-scale production in Europe 
for non-European countries, and significant production in some countries bordering 
the European Union. The increasing presence of Mexican groups involved in large-scale 
production of smokable crystal methamphetamine in Europe is of particular concern. 
This could result in increased availability of this drug in the European Union in future. 
Overall, current developments in the availability of precursor chemicals and in European 
synthetic drug-production capacity indicate that if demand for this drug increased in 
Europe, illicit producers would be able to respond quickly. While still relatively low, seizures 
of methamphetamine, both in terms of numbers and quantities, are increasing: with very 
large increases in the quantity of methamphetamine seized in Turkey together with reports 
of methamphetamine production in that country. Many of the indicators on drug use and 
some indicators of the drug market are ill-adapted to distinguish between amphetamine 
and methamphetamine. As a result, especially in view of the overall greater part played by 
amphetamine, they are likely to be insensitive to changes in methamphetamine use in 
Europe. Currently, the availability of other stimulants on the European drug market appears 
to be high. However, if this were to change, a threat exists that methamphetamine availability 
and use could grow rapidly. Given the prominent role played by this drug in the global market 
for stimulants and its association with both severe acute and chronic health problems, it 
must be considered one of the priority areas for drug monitoring. In the current environment, 
where new drug trends can emerge rapidly, contingency planning to improve Europe’s 
preparedness for any future escalation in problems in this area would also be beneficial.
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I Key findings 
 The market for methamphetamine in the European Union is small compared with the 
markets for other stimulant drugs, such as cocaine, amphetamine or MDMA, and has 
been relatively stable over the last 10 years or so. However, recent developments, such as 
seizures of unusually large amounts of crystal methamphetamine and the dismantling of 
large-scale production facilities in the European Union in 2019, could indicate that this 
is changing. The production and consumption of methamphetamine is at present mainly 
concentrated in a small number of Member States or specific user groups rather than being 
an EU-wide issue. 
Methamphetamine has been a feature of the drug problem in Czechia, Slovakia and 
Germany, as well as some Nordic countries, for a number of years. More recently, some 
other countries, including France, Spain and Turkey, have recorded notable increases in the 
number of seizures or quantities of methamphetamine seized. However, the majority of EU 
countries appear to have experienced only marginal or small increases in the availability of 
methamphetamine over the last years, reflected in seizures data.
Like many other drugs, methamphetamine is also available to consumers on darknet 
markets. The sale of methamphetamine on these marketplaces appears to have increased 
the amount of methamphetamine trafficked via post and parcel services within or via the 
European Union. However, the distribution of methamphetamine by EU-based vendors 
or to customers in the European Union remains limited compared with other substances 
available on these platforms.
Large quantities of methamphetamine have been seized in Turkey since the mid-2000s and 
Turkey now seizes more methamphetamine annually than all EU countries combined. This is 
likely a result of the smuggling of the drug from Iran, a major methamphetamine producer, 
into Turkey for export to Asian markets. However, there is also some methamphetamine 
manufacturing and consumption in Turkey, which should be closely monitored. 
The main drug precursors used for the production of methamphetamine are ephedrine 
or pseudoephedrine and BMK. BMK is produced within the European Union from 
alternative chemicals, such as APAAN (alpha-phenylacetoacetonitrile), APAA (alpha-
phenylacetoacetamide) and MAPA, which are imported from Asia, particularly China. 
Most of the methamphetamine sold in the European Union is produced in the 
European Union. Czechia is a centre for the production of the more potent d-isomer of 
methamphetamine (the type used for making smokable ‘crystal meth’), which is produced 
in small-scale illicit laboratories from medicinal products containing pseudoephedrine. Of 
the 300 illicit methamphetamine laboratories reported in the European Union in 2017, a 
total of 264 were found in Czechia. Member States surrounding Czechia including Austria, 
Germany, Poland and Slovakia have also dismantled small-scale illicit methamphetamine 
laboratories, but in much smaller numbers. 
Organised crime groups (OCGs) are involved in the medium- to large-scale production of 
methamphetamine in Czechia, the Netherlands and, potentially, on a smaller scale in the 
Baltic area. 
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In Czechia, the production of crystal methamphetamine for export to other EU Member 
States is dominated by Vietnamese OCGs. 
Dutch OCGs use their expertise and production facilities for synthetic drugs such as MDMA 
and amphetamine to also engage in the production of methamphetamine for export from 
the European Union to countries like Japan and Australia.
OCGs may produce methamphetamine on a small scale in Lithuania and Latvia for local 
consumption and export to other Baltic and the Nordic countries. However, only a few illicit 
laboratories have been detected in these countries in the last few years.
The production in small-scale ‘kitchen type’ laboratories is typically carried out by 
methamphetamine consumers to supply small circles of users, in various Member States. 
Such small-scale production is not thought to be linked to organised crime groups. 
Some methamphetamine produced outside the European Union is trafficked to lucrative 
markets in Asia via the European Union. OCGs use EU citizens as couriers in order to 
avoid border controls. Nigerian organisers or OCGs appear to orchestrate most of the 
trafficking of methamphetamine originating from West Africa via the European Union to 
Asia. Methamphetamine originating from Iran also appears to be trafficked via Turkey to the 
European Union and onwards to markets in Asia, particularly Japan.
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I Introduction
Methamphetamine is reported to be the most widely 
consumed synthetic stimulant in the world. In many countries 
it is reported as the second most prevalent illicit drug after 
cannabis. This results from both historical and more recent 
factors. Following its initial synthesis from ephedrine in 1919, 
methamphetamine use has evolved over the years. Originally a 
non-controlled substance used as a medicine, it was then used 
as a stimulant by the military in World War II. By the late 1940s 
it had become widely consumed in some parts of the world. 
Although it was controlled internationally by the UN Convention 
on Psychotropic Substances in 1971, it has been an illicit drug 
of increasing popularity. 
Today, methamphetamine is the cause of serious public health, 
social and security problems across the globe. The harms 
associated with methamphetamine use vary considerably 
depending on the route of administration and patterns of 
use, with injecting and smoking being particularly high-risk 
behaviours. Methamphetamine use can lead to problems, 
including cardiovascular and cerebrovascular conditions, 
dependence, psychological and psychiatric disorders, 
infectious diseases and death. Thus, the potential diffusion of 
this drug is a cause for concern. The problems associated with 
methamphetamine use are especially visible in North America 
and Asia, although its use is also spreading to new areas, 
notably to some countries in Africa and the Middle East, and in 
certain parts of the southern hemisphere. 
Although methamphetamine use remains limited in Europe 
as a whole, especially when compared to other stimulants 
like cocaine and amphetamine, it is the cause of significant 
harm in some Member States. In Czechia it accounts for one 
in every two admissions to specialised drug treatment. In 
addition, since the late 1990s, methamphetamine use has 
grown to become an important component of Slovakia’s drug 
problem. Diffusion is also occurring to some extent in other 
countries in central and eastern Europe, notably Germany 
and Austria. Moreover, methamphetamine is increasingly 
detected in the Nordic countries, particularly in Norway where 
it appears to be replacing amphetamine to a large extent. Data 
from wastewater studies show the use of methamphetamine 
in Finland and Cyprus. These developments, combined with 
the relative ease with which the drug can be produced, and 
evidence of growing methamphetamine production outside the 
areas in which it has historically been found, raise concerns 
about the potential for further diffusion of methamphetamine 
and related problems in Europe. 
This threat assessment provides a review of the key issues 
and latest developments relevant to understanding Europe’s 
methamphetamine problem today. It has been produced 
jointly by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and Europol. It has been compiled 
from information supplied to the EMCDDA and Europol by 
the Member States of the European Union and third parties. 
Key sources of information used in this report include the EU 
Serious organised crime threat assessment (Europol, 2017); 
statistical data reported annually to the EMCDDA by the 
Reitox network; information held by Europol, including data 
provided by the EU Member States for the mid-term review 
of the EU Serious organised crime threat assessment; data 
on precursors made available by the European Commission; 
international reports, such as those of the United Nations 
Office on Drugs and Crime (UNODC) and the International 
Narcotics Control Board (INCB); and the scientific literature. 
The report also relies on data concerning sites related to 
synthetic drug production that are dismantled and reported 
annually by the EU Member States to Europol and the EMCDDA. 
I Historical background
Methamphetamine was first synthesised from ephedrine in 
Japan in 1919 by Akira Ogata. Ephedrine had been isolated 
from the Ephedra vulgaris plant by another Japanese chemist, 
Nagayoshi Nagai, some years earlier (Zábranský, 2007). The 
drug was patented in 1920, then marketed in hydrochloride 
form by the Burroughs Wellcome company under the brand 
name Methedrine (Logan, 2002). 
In the 1920s and 1930s, the medical and paramedical use of 
methamphetamine and amphetamine (Benzedrine, Dexedrine) 
increased in Europe and in the West in general. For instance, 
amphetamine was prescribed for depression and other mood 
disorders in the United Kingdom, but was also sought out for 
its stimulant effects (by students, for instance). Problematic 
side effects of chronic and non-medical use of amphetamine, 
including hypertension, depression, dependence, and 
psychiatric disturbances have been documented since the late 
1930s (ACMD, 2005). Nevertheless, both amphetamine and 
methamphetamine enjoyed widespread acceptance as safe 
and beneficial drugs among the medical profession and the 
public at large, well into the 1960s. 
In 1938, the Berlin-based Temmler pharmaceutical company 
started production of methamphetamine under the brand 
name Pervitin (Griffiths et al., 2008). During World War II, 
Pervitin was widely distributed to German troops in an 
attempt to enhance performance and increase concentration, 
and became known in Germany as “pilot’s chocolate” 
and “pilot’s salt”. The drug also gained popularity among 
German civilians (UNODC, 2003; Zábranský, 2007). In Japan, 
methamphetamine was first commercially manufactured in 
1941. It was supplied to Japanese soldiers, especially pilots, 
and to workers in key war industries under the brand name 
Philopon from 1942 onwards. Methamphetamine use spread 
in the Japanese population, who dubbed the drug ‘shabu’ 
(Tamura, 1989). ‘Shabu’ and ‘yaba’ are names commonly used 
7 /23 
THREAT ASSESSMENTS I Methamphetamine in Europe
today for illicit methamphetamine tablets consumed mainly in 
parts of Southeast Asia. 
On the Allied side, although millions of methamphetamine 
tablets were supplied to US military personnel (AMCD, 2005), the 
stimulant given to soldiers was more commonly amphetamine, 
which again also resulted in some subsequent post-war 
diffusion of use to civilian populations (Zábranský, 2007). 
Fuelled by the sale of the enormous war surplus of 
amphetamines to the general population, this initial wave 
of synthetic stimulant use continued into the late 1940s. 
There was widespread medical and non-medical use of 
amphetamine in Europe (especially in Sweden and the United 
Kingdom), amphetamine and methamphetamine in North 
America (notably in the United States), and methamphetamine 
in the Far East (specifically Japan) (AMCD, 2005; Tamura, 
1989; UNODC, 2003; Zábranský, 2007). 
Although initial restrictions on the prescription and sale of 
amphetamine and methamphetamine products (tablets, 
ampoules, inhalers) were imposed in all three regions 
in the early 1950s, demand remained high, and use of 
amphetamines continued in the 1950s and 1960s. The 
overwhelming majority of the amphetamines available at that 
time were manufactured legally by pharmaceutical companies 
and prescribed by medical practitioners for a wide variety of 
disorders, including depression, attention deficit disorder, 
alcoholism, obesity and anorexia (AMCD, 2005; Tamura, 1989). 
During the 1960s in North America and Europe, supply 
channels began to shift and illicit sources of supply gradually 
emerged, probably responding to the increasing restrictions 
placed on the medical use of these drugs. In Europe, the 
United Kingdom and Sweden experienced increasing misuse 
of amphetamine from the 1950s, with amphetamine obtained 
from licit medical prescription being diverted into the illicit 
market. Over time, methamphetamine and amphetamine 
diverted from therapeutic use were replaced on the market 
by illicitly produced amphetamine sufate and, by the 1980s, 
methamphetamine had virtually disappeared from the United 
Kingdom’s illicit drugs market (AMCD, 2005). This pattern was 
common for most European countries where amphetamine, 
joined later by MDMA, was the main non-cocaine stimulant 
drug used for a considerable period. 
A notable exception to this is Czechia where the illicit 
production and use of methamphetamine has been a major 
component of the country’s drug problem since the 1970s. At 
that time, a simple formula for methamphetamine production, 
known locally as Pervitin, was rediscovered, probably in Prague. 
Production, usually by small groups of user-producers, was 
facilitated by the existence of the VUAB factory, which was an 
(1) d-Methamphetamine is also known as (S)-(+)-methamphetamine.
(2) l-Methamphetamine is also known as (R)-(–)-methamphetamine.
important manufacturer of ephedrine. Some of the factory’s 
output was diverted to the illicit market. Other medicinal 
products that contain ephedrine or pseudoephedrine, such 
as Solutan (later Modafen and Paralen plus), were widely 
available and were also used, together with other freely 
available chemicals, in the production of methamphetamine 
using the ‘reduction method’. Although the VUAB factory 
ceased production of ephedrine in 2003 (Griffiths et al., 2008), 
illicit methamphetamine production is still common in Czechia, 
with around 250 sites dismantled annually. 
I Consumer markets for methamphetamine in Europe
I Chemistry and physical form of methamphetamine
Methamphetamine is a synthetic substance that acts as a 
stimulant of the central nervous system and is closely related 
to amphetamine. Methamphetamine exists in two optical 
isomeric forms (enantiomers), d-methamphetamine (1) and 
l-methamphetamine (2). Both enantiomers are psychoactive, 
having stimulant effects (Kuczenski et al., 1995; Mendelson 
et al., 2006), but the d-enantiomer is more potent, and 
its effects last longer than those of the l-enantiomer. At 
high doses, the l-enantiomer is reported to produce an 
intoxication similar to that caused by the d-enantiomer, but 
its psychoactive effects are relatively short-lived and less 
desired by experienced injecting methamphetamine users 
(Mendelson et al., 2006). Illicit methamphetamine encountered 
in Europe is typically a mixture of the d- and l-enantiomers in 
equal proportions, known in chemistry as a racemic mixture 
(d,l-methamphetamine). Racemic methamphetamine and 
d-methamphetamine are expected to have comparable abuse 
liabilities (Mendelson et al., 2006).
In addition, methamphetamine may exist in two forms: base 
and salt. The pure base form is a clear, colourless, volatile 
oil, which is insoluble in water and can be readily converted 
into methamphetamine hydrochloride (the most prominent 
salt form) using hydrochloric acid. The hydrochloride salt 
form is a crystalline solid, which is soluble in water. In the 
methamphetamine powder found on the illicit market, 
granulated crystals are usually mixed with cutting agents such 
as lactose, dextrose or caffeine. Large white or translucent 
crystals of methamphetamine hydrochloride, suitable for 
smoking, can be produced from a starting material that 
has a high concentration of methamphetamine (base or 
hydrochloride). This is often called ‘ice’ or ‘crystal meth’, 
because of its appearance. Methamphetamine hydrochloride 
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is commonly sold in tablets as ‘shabu’ or ‘yaba’ in parts of 
Southeast Asia, but may also be found as an ingredient of 
tablets sold as ‘ecstasy’ in Europe.
The method by which methamphetamine is administered 
depends on the form of the drug available. Powder (racemic) 
methamphetamine is usually administered in the same 
way as amphetamine powder, either inhaled intra-nasally 
(snorted), ‘bombed’ (wrapped in cigarette paper and 
swallowed) or dissolved and ingested or injected. Although 
smokable in this form, it is the larger crystals of relatively pure 
d-methamphetamine hydrochloride (‘crystal meth’) that are 
normally smoked, often in small glass pipes, and these crystals 
may also be dissolved and injected or crushed and snorted. 
The purity of methamphetamine depends largely on the 
quality of the precursors used and the skills of the producing 
chemist, but also on the addition of cutting agents. Powder 
methamphetamine is more likely to contain adulterants and 
tends to be of lower purity than the crystal form of the drug. 
Adulteration of crystal methamphetamine, though apparently 
rare in Europe, has also been documented (EMCDDA and 
Europol, 2016). 
The methamphetamine powder found on the illicit drugs 
market is similar to amphetamine powder in many ways, 
including purity and appearance, and the two are often 
indistinguishable to both users and dealers. It is important 
to bear this in mind when considering the implications of 
a spread of methamphetamine use in Europe, since the 
close physical resemblance of the two drugs may facilitate 
the diffusion of methamphetamine in markets where 
amphetamine is currently the stimulant of choice, as seems to 
be the case in some northern European countries (see below). 
I Methamphetamine-related harms and responses
Several physical and mental health problems are associated 
with the use of methamphetamine, and these may vary 
depending on the route of administration. For example, when 
injected, there is an increased risk of infection with blood-borne 
viruses, including hepatitis C and HIV, if injecting equipment 
is shared among users. The smoking of methamphetamine 
is also linked to problems, particularly if it occurs in high-
dose ‘binges’ lasting several days. Although relatively few 
European countries have identified significant numbers of 
high-risk methamphetamine users (see ‘European consumer 
markets for methamphetamine’), it is possible that in some 
countries, amphetamine and methamphetamine may be used 
interchangeably by some people.
Most research findings on the health consequences of use of 
amphetamines come from the United States and Australia, 
where the smoking of crystal methamphetamine is the 
predominate form of use. Nevertheless, many of the findings 
also apply to the use of the drug in powder form or by injection, 
which are more common in Europe. Methamphetamine use 
can lead to a range of problems including cardiovascular 
and cerebrovascular conditions, dependence, psychological 
and psychiatric disorders, infectious diseases and death. 
Methamphetamine smoking is associated with respiratory 
damage, including pulmonary oedema, and teeth and gum 
decay (‘meth mouth’). Acute methamphetamine intoxication 
(‘overdose’) can lead to severe hyperthermia, kidney failure and 
heart attack. The most serious mental health harms associated 
with the use of amphetamines include psychosis, depression, 
suicidal behaviour, anxiety and violent behaviour (Darke et 
al., 2008). People seeking treatment for methamphetamine 
problems often present with high levels of other psychiatric 
problems, in particular psychosis, which can be induced or 
exacerbated by the use of stimulants (EMCDDA, 2014, 2015). 
Needle and syringe exchange programmes are effective in 
reducing the risks related to injection drug use, such as the 
transmission of infectious diseases, and broad access to a 
full supply of sterile syringes and other injecting equipment 
is recommended as a measure to reduce harms (ECDC and 
EMCDDA, 2011; MacArthur, 2014). Outreach health education 
and supervision of drug consumption are approaches 
that may help to reduce injecting risk behaviours. There is 
not yet a proven effective pharmacological treatment for 
methamphetamine dependence, although several stimulant 
substances are under trial. Pharmacotherapy is recommended 
as an adjunct to psychosocial treatment but it is not a primary 
component of treatment. There is evidence showing that two 
forms of psychosocial interventions, cognitive behavioural 
therapy and contingency management, can effectively reduce 
stimulant drug use and related problems, such as risky sexual 
behaviour. More information on this can be found in the Health 
and social responses to drug problems: a European guide 
(EMCDDA, 2017).
I European consumer markets for methamphetamine
By global standards, the size of the European consumer 
market for methamphetamine is limited, and has appeared 
relatively stable, although this may now be changing (see 
below). Under present practice, prevalence of use data 
on amphetamine and methamphetamine are generally 
aggregated and reported together as ‘amphetamines’, which 
makes it difficult to estimate the size of methamphetamine 
consumer markets. The value of the combined market is 
estimated to be about EUR 1 billion, implying that at least 
62 tonnes of amphetamines is consumed annually in Europe 
(EMCDDA and Europol, 2019). Despite the lack of quantitative 
data on methamphetamine use, other data, such as global 
drug seizures suggest that methamphetamine is the synthetic 
stimulant most consumed at world level (UNODC, 2018, 2019). 
In 2017, for instance, some 184 tonnes of methamphetamine 
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was seized worldwide, 55 % more than in 2016, compared 
with 58 tonnes of amphetamine. However, just 0.7 tonnes 
of methamphetamine was seized that year in Europe, where 
methamphetamine is still a minor player in the overall 
synthetic stimulant market. Thus, it is likely that the majority 
of the more than 1.2 million young Europeans (15-34) 
that have used amphetamines during the last year, used 
amphetamine rather than methamphetamine (EMCDDA, 
2019c; UNODC, 2019). 
Both amphetamine and methamphetamine can be taken 
orally or nasally; in addition, a significant part of the high-risk 
use in some countries involves the use of these drugs by 
injection. Although methamphetamine can also be smoked, 
this route of administration is not frequently reported in 
Europe. Amphetamine and methamphetamine may be sold 
interchangeably (EMCDDA and Europol, 2016).
Consumption of synthetic stimulants in Europe historically 
has been dominated by amphetamine and MDMA, with 
methamphetamine use being largely confined to Czechia 
and Slovakia, where the drug is known as ‘Pervitin’ and 
‘piko’. However, recent reports have highlighted changes, 
and the development of methamphetamine use outside 
these two long-standing consumer markets. Europe’s 
current methamphetamine problem has no single face, and 
distinct patterns of use among different user populations 
are emerging in some parts of Europe. These range from 
socially integrated users who snort or swallow the drug, to 
marginalised users who inject or smoke methamphetamine. 
Wastewater analysis and other data show that 
methamphetamine use now appears to be present in several 
other Member States including Cyprus, the east of Germany, 
Spain and northern Europe (see Figure 1). Wastewater 
data from 7 years of monitoring, however, showed no major 
changes in the general patterns of methamphetamine use 
observed across Europe. 
Available data for 2017 indicate that methamphetamine was 
seized more often than amphetamine in Cyprus, Czechia, Italy, 
Latvia, Lithuania, Slovakia and Turkey. This implies that users 
of amphetamines may be using methamphetamine rather than 
amphetamine in those countries.
According to the most recent information available for Czechia, 
high-risk methamphetamine use among adults (15-64) was 
estimated at around 0.50 % in 2017, corresponding to 34 700 
users. This is an increase from the 20 900 users estimated in 
2007, though numbers have been relatively stable in recent 
years. In addition, it should be noted that injecting remains the 
primary mode of methamphetamine use in Czechia, where the 
drug is often used in the context of polydrug use with opioids 
(EMCDDA, 2019a). 
In Slovakia, where methamphetamine predominates over 
amphetamine, last-year prevalence of use of amphetamines 
in the 15-34 age group was estimated in 2015 (latest figures 
available) at 0.8 % and lifetime prevalence among all adults 
(aged 15-64) was 1.4 % (EMCDDA, 2018). 
mg/1 000 population/day
NB: Mean daily amounts of methamphetamine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year 
from 2011 to 2018.
Source: Sewage Analysis Core Group Europe (SCORE).
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FIGURE 1
Methamphetamine residues in wastewater in selected European cities: trends and most recent data
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The European School Survey Project on Alcohol and Other 
Drugs, carried out every 4 years, estimated lifetime prevalence 
of use of amphetamines among school students aged 15-16 
years at 1 % in Czechia in 2015, down from a peak of 5 % in 
1999, and at 1 % in Slovakia in 2015, the same as in 1999 
(EMCDDA, 2018; Hibell et al., 2000).
The emergence of the smoking of crystal methamphetamine 
in Greece and Turkey, and to a lesser extent in Cyprus, is a 
cause for concern. Use of methamphetamine in crystal form, 
known locally as ‘sisa’ or ‘shisha’ (the Persian word for glass), 
has been reported by low-threshold and treatment services 
in Greece since 2010. Most users smoke the drug in glass 
pipes but some inject it. Users in Athens have reported that 
methamphetamine is used mainly by young people, groups of 
immigrants and users of heroin (EMCDDA, 2014). 
In a study of drug residues identified in syringes collected 
in six European cities, methamphetamine was not found 
at all in Amsterdam, Budapest or Lausanne (N = 81, 226 
and 233, respectively). In Paris, methamphetamine was 
detected in 3 of the 259 syringes and in Glasgow in 20 of 
195 syringes analysed. The situation in Helsinki was markedly 
different, with 136 of the 284 tested syringes found to contain 
methamphetamine, suggesting that injection as a mode of 
methamphetamine use is more common there than in the 
other cities (EMCDDA, 2019b).  
Methamphetamine use seems to be increasing among specific 
user groups, such as clubbers and men who have sex with 
men. Of particular concern are reports of methamphetamine 
use, including injection, among groups of men who have sex 
with men in metropolitan areas such as London and Paris 
in the context of so-called ‘slamming’ or ‘chemsex’ parties 
(Adfam and London Friend, 2019; EMCDDA, 2014). 
Overall, methamphetamine consumption patterns appear to 
have remained relatively stable across Europe, but signs that 
use of the drug is spreading to new countries have emerged 
in recent years. Indeed, although problems associated with 
the drug remain concentrated in Czechia and Slovakia, which 
together account for more than 65 % of the reported 4 900 
methamphetamine clients entering treatment in Europe in 
2017, there have been moderate but steady increases in 
the numbers entering treatment for problems associated 
with methamphetamine in EU countries reporting data 
such as Bulgaria, Cyprus, France, Greece and the United 
Kingdom between 2013 and 2017 (EMCDDA, 2019c). A 
new development should also be noted with some concern: 
Turkey reported the highest number of methamphetamine 
clients after Czechia and Slovakia in 2017 (EMCDDA, 2019). 
Due to the chronic and acute harms associated with the use 
of methamphetamine, the potential diffusion of the drug 
warrants vigilance. 
I Methamphetamine production
I Current production methods in Europe
Methamphetamine can be produced using a number of 
different techniques relying on a variety of precursor chemicals. 
The most common production methods in Europe rely on 
pseudoephedrine, ephedrine or BMK, and the end-products 
that can be made, their quality and quantity, strongly depend 
on the availability of these precursors and the expertise of the 
producers.  
TABLE 1 
Key information on the production of different forms of methamphetamine hydrochloride available in the European Union
Form Description Precursor Production locations
d-Methamphetamine High-potency crystal form 
suitable for smoking
Ephedrine or pseudoephedrine typically 
extracted from medicines
BMK may also be used, but this is less 
common in Europe and requires an 
extra production step using tartaric acid
Czechia: small and mid-scale
Austria, Bulgaria, Germany, Poland and 
Slovakia: small-scale
Netherlands: small, mid and large-scale
Racemic methamphetamine
(equal mixture of d- and 
l- forms)
Mid-potency powder used in 
similar way as amphetamine
BMK Netherlands: mid and large-scale
Lithuania: small to mid-scale
l-Methamphetamine Lower potency form 
used in medicines, e.g. 
decongestants
Not deliberately produced on its own in 
illicit labs in Europe
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Ephedrine and pseudoephedrine
Ephedrine and pseudoephedrine are internationally controlled 
drug precursors. They are the main precursors used in the 
production of methamphetamine in Bulgaria, Czechia, 
Germany, Poland, Slovakia and a number of other Member 
States. Production based on ephedrine and pseudoephedrine 
results in d-methamphetamine (Table 1). These two 
substances can be extracted from medicines, and some EU 
Member States such as Czechia, and more recently Germany 
and Poland, have implemented national restrictions on the sale 
of such medicines. In these countries, sales are restricted to 
small packet sizes sold under the supervision of a pharmacist. 
However, there is no harmonised approach to this at EU level, 
and the sale of medicines containing pseudoephedrine or 
ephedrine is not restricted in all Member States. This has 
given rise to the trafficking of such medicines from countries 
with less restrictive sales regulations to countries where 
methamphetamine production takes place. 
Benzyl methyl ketone (BMK) 
BMK is a drug precursor for amphetamine as well as 
methamphetamine and is an internationally controlled 
substance. Around 2011, in response to strict controls 
preventing the diversion of BMK (also called phenyl-2-
propanone or P-2-P) for the production of amphetamine in the 
European Union and to various improvements to the precursor 
monitoring regime, organised crime groups started to import 
large quantities of APAAN (alpha-phenylacetoacetonitrile), a 
chemical which can be readily converted into BMK. China is 
the main source of APAAN imported into the European Union, 
where it is often converted into BMK in dedicated laboratories. 
However, following the scheduling of APAAN in the European 
Union in December 2013 and at international level in October 
2014, alternative chemicals have appeared: first glycidic 
derivatives of BMK, then APAA and then MAPA. The dynamic 
and rapidly changing nature of the precursor market is evident 
from the declining number of incidents involving APAAN and 
the concomitant increase in incidents related to APAA between 
2012 and 2018 (Figure 2). In 2018, the emergence of MAPA 
suggests that drug producers may be preparing for the impact of 
control measures on APAA, introduced at the beginning of 2019.
Other production methods
Chloroephedrine is a precursor for the production of 
d-methamphetamine. Multi-tonne quantities of this precursor 
were discovered during law enforcement operations in 
Germany and Czechia in 2014. Methamphetamine produced 
from chloroephedrine is similar to methamphetamine 
(3) Commission Delegated Regulation (EU) 2016/1443 of 29 June 2016 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council 
Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances. 
produced from ephedrine and pseudoephedrine. 
Chloroephedrine is a chemical intermediate produced as 
part of the methamphetamine synthesis process and has no 
legitimate use. Since July 2016, both chloroephedrine and 
chloropseudoephedrine are scheduled as drug precursors 
at EU-level (3). These precursors do not seem to have gained 
traction in methamphetamine production in Europe, perhaps 
due to the availability of alternative substances coupled with 
the rapid response from the regulatory systems. 
Producers of methamphetamine are likely to continue to 
innovate and identify additional precursors, alternative 
chemicals and production methods if the controlled precursors 
such as pseudoephedrine, ephedrine or BMK become 
unavailable or prohibitively expensive, as illustrated by the 
switch from APAAN to APAA and more recently to MAPA. 
FIGURE 2
Incidents involving APAAN, APAA and MAPA reported to INCB, 
2012-18  
Source: INCB (2019)
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An apparently marginal but worrying development in the 
European Union is the appearance of non-scheduled 
substances that can be easily converted into illicit drugs 
without resorting to the usual drug synthesis methods. 
Although technically these substances may be considered as 
precursors, they are fundamentally different to the controlled 
drug precursors, as they contain the full illicit drug molecule 
with a protective chemical group attached, rendering it a 
different chemical entity and therefore outside the international 
control regimes for drugs and drug precursors. This is another 
example of innovation by illicit drug producers, using what 
are known in organic chemistry as protection/de-protection 
techniques. These techniques are also used to minimise the 
risks associated with the international trafficking of controlled 
drugs and precursors. 
This was first documented in Europe in December 2016 
when N-t-BOC-MDMA and N-methoxycarbonyl-MDA were 
detected in the Netherlands. Using a rudimentary process of 
heating in acidic conditions for a relatively short time, these 
substances are easily converted to the illicit drugs MDMA and 
MDA respectively. According to the INCB, the first detection of 
N-t-BOC-MDMA was in Australia in 2015. The corresponding 
methamphetamine derivative, N-t-BOC-methamphetamine 
was identified in China in 2015 and in New Zealand in 
January 2017, where it was found in a consignment imported 
from China (INCB, 2018). As of August 2019, N-t-BOC-
methamphetamine has not been reported in Europe.
I Production trends in the European Union
Most of the EU Member States report that there is no or 
only limited production of methamphetamine on their 
territory. There are three identifiable production centres for 
methamphetamine in the European Union: Czechia and areas 
bordering Czechia in neighbouring countries; the Baltic States 
with a focus on Lithuania; and the Netherlands. In addition, 
Bulgaria regularly reports the detection of small-scale 
laboratories. 
Czechia and surrounding area
For reasons outlined in ‘Historical background’ 
(page 6), Czechia has long been a centre of significant 
methamphetamine production. The number of laboratories 
manufacturing methamphetamine discovered by Czech law 
enforcement authorities has remained stable over the period 
2015-2017, with 264 illicit laboratories dismantled in 2017 
(Police of the Czech Republic, 2017) (Table 2). Although 
many are small-scale, there appears to have been an increase 
in the production capacity of some laboratories over the 
same period, perhaps due to the involvement of Vietnamese 
OCGs (see ‘Organised crime groups’, page 18). Czechia 
accounts for the largest number of methamphetamine 
production laboratories in Europe and an estimated 6.5 tonnes 
is consumed annually in the country (EDMR, 2019). Small 
numbers of small-scale, ‘kitchen laboratories’ continue 
to be discovered elsewhere, predominantly in regions of 
Austria, Germany, Poland and Slovakia bordering Czechia 
(see Table 2). There have been some indications that a small 
portion of production has been displaced from Czechia to the 
Netherlands in recent years. 
In addition to domestic Czech OCGs, Vietnamese OCGs 
have become involved in the production of ‘crystal meth’ 
(d-methamphetamine) in Czechia, supplying the drug to 
consumers in the country, as well as in bordering Member 
States and Norway. 
In Czechia, methamphetamine is produced mainly from 
ephedrine or pseudoephedrine, which is extracted from 
medicinal products originating mainly in European countries 
and trafficked by land. Until recently, Turkey was reported 
to be the source of such medicines, which were trafficked 
by land, transiting countries including Bulgaria, Hungary, 
Poland, Romania and Slovakia. However, the INCB reports that 
Turkey is less often identified as a source, and that controls 
implemented to tackle the problem are having the desired 
effect (INCB, 2019). The national police in Czechia now 
report that Poland is a key transit country for such medicines 
diverted from elsewhere in the European Union (Police of the 
Czech Republic, 2018). The production of methamphetamine 
detected in Poland, though at a low level, shows some signs 
of a possible increase. In 2017, eight illegal laboratories 
TABLE 2
Number of dismantled methamphetamine laboratories reported in the European Union, 2015-17
Czechia Bulgaria Germany Poland Netherlands Slovakia Lithuania Hungary Spain Total
2015 263 12  9 2 2 3 2 1 0 294
2016 261 10 11 5 2 2 0 0 0 291
2017 264  6  4 8 9 7 1 0 1 300
Source: Data reported to EMCDDA or Europol 
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producing methamphetamine were dismantled by Polish law 
enforcement authorities, compared with five in 2016 and only 
two in 2015. Moreover, it is reported that the laboratory set-ups 
are becoming more professional. This apparent increase 
in production is attributed to Polish as well as Czech and 
Vietnamese OCGs. Polish OCGs are believed to be significant 
suppliers of pseudoephedrine extracted from medicinal 
products used for the production of methamphetamine in 
Czechia. Time will tell if the changes to legislation in Poland, 
introduced in June 2015 and early 2017, intended to limit the 
availability of pseudoephedrine, will have an impact on the 
availability of the precursor in Czechia. In addition, in 2016, 
new Czech legislation introduced higher sentences of up to 
18 years of imprisonment for individuals convicted of drug 
production; however, it is too early to assess if this has had any 
deterrent effect. 
Lithuania
Few methamphetamine production facilities have been 
dismantled in Lithuania in recent years (one in 2017 and 
two in 2015). There are, however, indications that production 
may still be going on there. Methamphetamine couriers 
and shipments linked to Lithuanian OCGs are frequently 
intercepted in Member States in the region such as Estonia 
and Latvia en route to  Finland, Sweden and Norway. Analysis 
of the methamphetamine seized on this route indicates 
that it has been produced from the precursor BMK (which is 
typically produced from alternative chemicals) rather than 
pseudoephedrine or ephedrine.
The Netherlands and Belgium
The Netherlands is the main centre of synthetic drug production 
in Europe. Large-scale illicit laboratories, mainly producing 
MDMA and amphetamine, are dismantled regularly in the 
country. Methamphetamine production in the Netherlands 
was previously limited compared to MDMA and amphetamine, 
with Dutch law enforcement detecting small-scale laboratories 
producing methamphetamine at a rate of 1 or 2 per year over 
the past decade. However, the situation is changing, as recent 
information suggests that some Vietnamese groups may 
have shifted their methamphetamine-production operations, 
based on ephedrine or pseudoephedrine, from Czechia to 
the Netherlands. It is also important to note that large-scale 
laboratories producing methamphetamine from BMK have 
been found in the Netherlands in the past and more recently in 
Belgium (see below). 
Methamphetamine produced from BMK is in the racemic 
form (see Table 1), however, it is possible to produce 
d-methamphetamine from BMK by employing an additional 
processing step involving the use of tartaric acid. This process 
has been identified in large-scale illicit laboratories dismantled 
in the Netherlands. The potent d-methamphetamine in 
smokable crystal form is in particular demand in markets 
outside the European Union, such as Japan and Australia, 
where 1 gram can fetch as much as EUR 730, and the 
large-scale production output of the Netherlands appears 
to be primarily intended for these non-EU destinations. In 
evidence of this are the several multi-kilogram shipments of 
methamphetamine produced in the Netherlands that have 
been seized in Australia in recent years. However, in some 
cases methamphetamine produced in the Netherlands may 
be destined for the consumer markets of other EU Member 
States. For example, Spain and to a lesser degree Poland 
report that some of the methamphetamine on their drug 
markets comes from the Netherlands. 
In early 2019, indications emerged that Mexican suspects are 
involved in the supply and manufacture of methamphetamine 
in the European Union, possibly in cooperation with Dutch and 
Belgian OCGs, although clear links between these suspects 
and Mexican OGCs have not been established at this stage. 
Mexican OCGs have been involved for many years in the 
manufacturing of large quantities of methamphetamine in 
Mexico and Central America, chiefly for export to the United 
States but also for markets in Asia and Oceania, and they are a 
significant threat. 
Mexican suspects were implicated in the operation of an illicit 
methamphetamine laboratory on an 85-metre barge moored 
in Moerdijk (Netherlands) in May 2019. Law enforcement 
authorities seized methamphetamine oil with a street value of 
more than EUR 4.5 million, 6 kilograms of d-isomer or ‘crystal’ 
methamphetamine and arrested a Dutch suspect, the captain 
of the boat, as well as three Mexican nationals suspected 
of operating the methamphetamine production laboratory 
(Boffey, 2019). The investigation into the production operation 
also revealed links to a known Dutch chemist previously 
involved in large-scale synthetic drug production in the 
Netherlands. 
In June 2019, Dutch law enforcement authorities seized 
2.5 tonnes of methamphetamine in Rotterdam with a 
street value of hundreds of millions of euros. The seized 
methamphetamine was believed to be intended for markets 
other than the Netherlands (Reuters, 2019). The shipment 
arrived in the Netherlands via Spain, but the involvement 
of Mexican nationals and possibly OCGs in the production 
and trafficking is suspected. The premises where the 
methamphetamine was seized are linked to companies 
registered in Spain and Mexico. This trafficking operation was 
also linked to outlaw motorcycle gangs (OMCGs) active in the 
Netherlands.
In addition, in August 2019, Dutch law enforcement authorities 
seized 32 kilograms of methamphetamine in a warehouse in 
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Hilversum and arrested three suspects. The methamphetamine 
originated from Mexico and was hidden inside an industrial 
magnet during transit from Mexico to the European Union 
(Pieters, 2019).
Methamphetamine is also increasingly trafficked to the 
European Union from Mexico using post and parcel 
services as well as by couriers. It is clear that some of the 
methamphetamine produced in the European Union with 
Mexican involvement and the methamphetamine sent to 
the European Union from Mexico is intended for markets in 
Asia and Australia; however, some may also be distributed in 
Europe. The market for methamphetamine in the European 
Union remains much smaller than the markets for other 
synthetic stimulant drugs such as amphetamine or MDMA. 
Nevertheless, the emergence of trafficking networks and the 
expansion of methamphetamine production in the European 
Union need to be closely monitored.  
The production of methamphetamine in the European Union 
outside these production centres appears to be limited in 
terms of the number of laboratories and the overall quantities 
manufactured, with production in such settings almost 
exclusively based on ephedrine or pseudoephedrine extracted 
from medicines. 
I External methamphetamine production affecting the European Union
Methamphetamine is produced and consumed in several 
regions of the world in much larger quantities than in the 
European Union, with Asia and North America identified 
as the largest markets for the drug at global level (UNODC, 
2017a). However, even though most of the methamphetamine 
consumed in the European Union is thought to be produced 
in the European Union, large-scale production and trafficking 
of methamphetamine elsewhere in the world does have an 
impact on the European Union. 
In some cases, the European Union has been a region of origin 
for ephedrine and pseudoephedrine trafficked to regions with 
significant methamphetamine production, such as Mexico, 
Central America and Iran. Methamphetamine may also be 
smuggled into Europe on a limited scale to meet demand for 
the drug among specific diaspora communities originating in 
Southeast Asia. 
However, the two most significant methamphetamine 
production regions outside the European Union with an 
impact on Member States are likely to be Iran and West Africa. 
Methamphetamine produced in these regions is trafficked 
to consumer markets in Australia and Asia (Japan, Thailand, 
Malaysia, Indonesia, etc.) via transportation hubs in the 
European Union. Although some methamphetamine produced 
in Iran and West Africa may be sold on EU drug markets, the 
evidence available would suggest that this is on a very limited 
scale. OCGs trafficking methamphetamine via Europe primarily 
rely on couriers carrying methamphetamine concealed in 
their luggage. These, often European, couriers mostly use air 
travel, changing flights within the European Union to attempt 
to mask their original point of departure and their intended 
destinations. 
Europe outside the European Union
Small- and medium-scale production of methamphetamine 
takes place in countries neighbouring the European Union 
including the Western Balkan region and Turkey. 
Turkey
In 2017, Turkey was the country in Europe seizing the largest 
amount of methamphetamine (658 kilograms). A proportion of 
this total was probably imported from Iran, but it is likely that 
some was produced in Turkey, as the dismantlement of several 
methamphetamine production facilities, often in connection 
with the arrest of Iranian nationals, has been reported in the 
Turkish press since 2017. The quantities of methamphetamine 
or precursors seized on many of the sites suggest that mid-
to-large-scale production was taking place (Ensonhaber.com, 
2017, 2019; Haberturk.com, 2019; Haberayyildiz.com, 2017 ; 
Yenisafak.com, 2018). 
Ukraine and Russia
Seizure data for methamphetamine, ephedrine and 
pseudoephedrine indicate that some production of 
methamphetamine may also take place in Ukraine. For 
example, in 2016 with 253 kilograms, Ukraine seized more 
ephedrine than all the EU Member States combined (INCB, 
2018). However, so far there have been no indications that 
methamphetamine produced in Ukraine is trafficked to the 
European Union in significant quantities. 
There is no information available on the extent of 
methamphetamine production in Russia, which seized 
3 kilograms of ephedrine in 2016 (INCB, 2018).
West Africa
Several methamphetamine production facilities have been 
dismantled in West Africa over the last 10 years but the 
available data are weak and unlikely to reflect the scope of 
methamphetamine production in West Africa or in Africa as 
a whole. There are indications that the methamphetamine 
produced in Africa is primarily d-methamphetamine. In March 
2016, Nigerian authorities dismantled an industrial-scale 
illicit laboratory, where methamphetamine was produced 
using benzaldehyde and other chemicals following a method 
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known to be used in Mexico (INCB, 2018). This was one of six 
methamphetamine laboratories reported dismantled by Nigeria 
in the 2014-17 period (UNODC, 2019). In addition, Nigeria has 
reported seizing large amounts of ephedrine in recent years, 
including 785 kilograms in 2015 and 444 kilograms in 2016, 
though in in most cases the precursor appeared to be en route 
other African countries (INCB, 2019).
Reports indicate that methamphetamine is also produced in 
other West African countries. For example, Burkina Faso was 
reported to the EMCDDA as the country of manufacture of 
methamphetamine seized in Belgium in 2016. In 2015, Mali 
reported the seizure of 12 kilograms of ephedrine to the INCB 
and in 2017, Benin reported seizing 152 kilograms of ephedrine 
and 295 kilograms of ephedrine preparations (INCB, 2019). 
As already noted, Australia is a significant destination market 
for methamphetamine trafficked via the European Union by 
various OCGs, including Nigerian OCGs using EU citizens as 
couriers. Countries in the European Union and elsewhere have 
been detecting of large numbers of drug couriers originating 
from West Africa for a number of years, and it seems likely that 
methamphetamine production takes place on a larger scale in 
West Africa than is currently suggested by official figures. 
It is likely that methamphetamine production may be taking 
place elsewhere in Africa. For instance, South Africa, Egypt 
and Kenya have also reported dismantling methamphetamine 
production facilities in the recent past (UNODC, 2014a, 2019). 
However, many seizures of illicit facilities may go unreported 
due to the lack of developed drug monitoring systems in 
Africa. Methamphetamine couriers departing from countries in 
eastern and southern Africa have been arrested in EU Member 
States, but the origin of the intercepted drugs is uncertain.
Iran 
Significant amounts of methamphetamine are likely to 
be manufactured in Iran for domestic and international 
consumption, though some Iranian methamphetamine 
producers appear to have relocated their operations 
to Turkey (see above) and Afghanistan (see below). 
Although the numbers of dismantled illicit laboratories and 
methamphetamine seizures have declined, production of 
the drug in Iran appears to remain at a high level. In 2017, 
Iran reported seizing 2.3 tonnes of methamphetamine (down 
from 3.7 tonnes in 2013) and dismantling 141 laboratories 
(UNODC, 2019). However, because Iran has not reported 
seizures of either ephedrine or pseudoephedrine to the INCB 
since 2011, it is difficult to assess the scope of the illicit 
trade in methamphetamine precursors in the country (INCB, 
2018). It is likely that significant quantities of ephedrine and 
pseudoephedrine are trafficked to Iran from the Kurdistan 
region of Iraq, which imports these precursors mainly from 
Jordan (INCB, 2019; Mansfield and Soderholm, 2019). 
The INCB also notes that more methamphetamine may be 
manufactured in Iran starting from BMK than was previously 
the case (INCB, 2019). Methamphetamine produced in Iran is 
trafficked to markets in the Middle East and Southeast Asia, 
often using air couriers transiting European airports. Although 
such incidents have not been reported as frequently as in the 
past, Turkey continues to report that some methamphetamine 
is imported into Turkey by land from Iran and subsequently 
flown to Asia via Istanbul airport. 
Afghanistan
A potentially important development has been noted in 
Afghanistan, where methamphetamine production is 
increasing, initially as a result of the relocation of some Iranian 
producers on Afghan territory. Access to methamphetamine 
precursors is reported to be easier in Afghanistan than 
in Iran, which introduced measures restricting access to 
medicines containing ephedrine and pseudoephedrine in 
2012. In Afghanistan, the process used was initially based 
on the extraction of ephedrine and pseudoephedrine from 
medicines. This may still be the case, at least to some extent, 
as according to the INCB Afghanistan’s official requirements 
of bulk pseudoephedrine are incommensurate with the 
country’s pharmaceutical need and there is a risk that 
some of it could be diverted to produce methamphetamine 
(INCB, 2019). However, alternative starting materials may 
now be used. Furthermore, it has recently been reported 
that methamphetamine producers in Afghanistan are 
using ephedrine extracted from Ephedra plants growing 
wild in mountainous regions of the country (Mansfield and 
Soderholm, 2019). Some of these producers have stated that 
they achieved a 50 % reduction in production costs by using 
plant material (Mansfield, 2019). 
It will be important to monitor this phenomenon, given the 
significant traffic of heroin to the European Union from 
Afghanistan via various trafficking routes described elsewhere 
(EMCDDA and Europol, 2019). 
Mexico
Mexico is a major producer of methamphetamine, mainly for 
the US market, and it is certain that some methamphetamine 
is trafficked on a regular basis from Mexico via the European 
Union to destination markets in Asia and Australia (see above). 
However, seizures at airports indicate this to be a much 
less significant phenomenon compared to the trafficking of 
methamphetamine from West Africa or Iran, although it seems 
to be growing.
16 /23 
THREAT ASSESSMENTS I Methamphetamine in Europe
I Trafficking and distribution of methamphetamine and its precursors in Europe
Given that most EU countries report limited or no production 
of methamphetamine on their territories, and as most of the 
methamphetamine consumed in the European Union would 
appear to be produced in the European Union, trafficking 
between Member States is currently the primary mode of 
distribution of the drug to EU consumer markets. 
Intra-European trafficking of methamphetamine links the 
centres of production such as Czechia and the Netherlands to 
Member States with little or no methamphetamine production. 
As well as the road and rail networks, post and parcel services 
are increasingly being used to traffic methamphetamine 
across the European Union. The increase in parcel trafficking is 
likely linked to increased online trading in methamphetamine 
and other illicit drugs on darknet markets. Intra-European 
smuggling via passenger aircraft is thought to be largely 
absent, due to the intense screening that goes on at airports 
for the detection of explosives and other contraband. The 
situation with private aviation is less clear, however, it is 
reasonable to assume that trafficking of methamphetamine 
takes place in the context of polydrug trafficking using general 
aviation.
I Seizures of methamphetamine and precursors
The number of seizures of methamphetamine has shown an 
overall upward trend since 2002 but with signs of stabilisation in 
recent years; the quantity seized has been increasing, albeit with 
some fluctuation, since 2009 (Figure 3). With 9 000 seizures 
amounting to 0.7 tonnes reported in the European Union in 
2017, methamphetamine seizures are at much lower levels 
than those of amphetamine (35 000 seizures and 6.4 tonnes). 
In 2017, France (122 kilograms), Germany (114 kilograms) 
and Czechia (93 kilograms) seized the largest amounts in the 
European Union. In 2017, Turkey seized the largest quantity 
of methamphetamine in Europe (658 kilograms), a similar 
amount to that reported for the European Union and Norway 
(662 kilograms) (EMCDDA, 2019c). 
Data collected by the European Commission regarding 
seizures of precursors in the European Union showed that in 
2017, Member States seized 25 kilograms of ephedrine and 
13 kilograms of pseudoephedrine in bulk powder form as well 
as 3 506 litres of BMK and 5 065 kilograms of APAAN. The 
trafficking of small quantities of certain chemical reagents to 
Member States that do not report production on their territories 
indicates that small-scale amateur production may take place 
in those Member States. In addition to these scheduled drug 
precursors, in 2017 more than 10 tonnes of APAA and 4 tonnes 
of glycidic derivatives of BMK were seized; these substances 
FIGURE 3
Number of methamphetamine seizures and quantity seized: trends and 2017 or most recent year 
Source: EMCDDA, European Drug Report 2019: Trends and Developments
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can be readily converted to BMK for amphetamine or 
methamphetamine synthesis and are not currently scheduled 
substances. Open source information monitoring continues 
to detect the interception of significant quantities of APAA: 
1.4 tonnes in Luxembourg and 4.2 tonnes in the Netherlands 
at the end of 2017 and 2.5 tonnes in Bulgaria in 2018. The 
fact that greater quantities of non-scheduled substances than 
scheduled substances are seized confirms the recent trend 
of precursor substitution described in ‘Current production 
methods in Europe’ (page 10). 
Turkey seems to have emerged recently as a producer of 
methamphetamine (see above), and it is an important transit 
country for various illicit commodities smuggled into the 
European Union including heroin and certain counterfeit 
goods. Methamphetamine originating from Iran and precursors 
such as ephedrine and pseudoephedrine from other source 
countries transit Turkey before reaching the European Union. 
Precursors are typically trafficked onwards to production 
centres in the European Union, while methamphetamine 
is often intended for trafficking to markets in Asia. EU 
Member States are also used as transit points for the 
trafficking of precursors. Large shipments of ephedrine and 
pseudoephedrine destined for different countries outside the 
European Union have been intercepted in the Netherlands. 
I Prices and purities 
The average reported purity is usually higher for 
methamphetamine than for amphetamine, although the 
average may be inflated by the influence of the higher purity 
crystalline from. The prices for methamphetamine vary 
greatly across the European Union and even within individual 
Member States, at both the retail and wholesale levels, and 
methamphetamine in crystalline form commands higher prices 
than the powder form. Recent information suggests that the 
larger crystals of methamphetamine command premium 
prices. Among the 14 countries with information, the most 
commonly reported price for 1 gram of methamphetamine 
varied from EUR 7.5 in Bulgaria to EUR 160 in Belgium, with 
Czechia reporting EUR 37 and neighbouring Slovakia almost 
twice as much (EUR 65). Available data on the most common 
methamphetamine prices at the wholesale level indicate that 
prices per kilogram vary from about EUR 3 000 in Czechia to 
EUR 40 000 in Slovakia (Figure 4). 
The retail price of methamphetamine tends to be lowest 
closest to centres of production. For instance, the price 
in Germany varies greatly across regions  depending 
on their distance from Czechia, the primary source of 
methamphetamine consumed in Germany. The price of 
methamphetamine in urban centres such as Berlin can still be 
significantly higher than in surrounding areas. Overall, there is 
no clear picture on trends in methamphetamine prices across 
Europe, as the data available at present do not discriminate 
between crystalline and powder forms of the drug.
According to Australian law enforcement experts, the 
wholesale price of methamphetamine in Australia ranges 
from EUR 50 000 to EUR 170 000. Given these high prices, it 
is understandable that this market is seen as very lucrative by 
organised crime groups (EMCDDA and Europol, 2019). 
I Trafficking modi operandi 
European law enforcement authorities have identified a 
number of modi operandi associated with the trafficking of 
FIGURE 4 
Retail and wholesale methamphetamine prices in 2017, or the most 
recent year in countries providing data 
Source: Source: EMCDDA and Europol
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methamphetamine within Europe, particularly the use of 
couriers and the use of fast parcel and postal services for 
distributing small quantities.
Wholesale trafficking of methamphetamine
There is little information available regarding the trafficking of 
methamphetamine in large quantities across Europe. However, 
compared with other synthetic drugs such as amphetamine 
or MDMA, it appears to be marginal. Available information 
suggests that organised crime groups involved in the trafficking 
of methamphetamine from Czechia to neighbouring countries 
or to the Nordic countries have switched to trafficking larger 
consignments through couriers, instead of the formerly 
common practice of users travelling to Czechia to buy small 
quantities of the drug (Police of the Czech Republic, 2016).
The most common modi operandi associated with the 
trafficking of methamphetamine from the Netherlands include 
the use of couriers, shipments concealed in air freight or 
containers or the use of fast parcel and postal services. The 
latter method is associated with the sale of methamphetamine 
on online marketplaces.
Use of postal systems and parcel services
Some methamphetamine is trafficked to and via Europe in 
relatively small (under one kilogram) quantities, concealed in 
parcels and packages. The use of the postal system to traffic 
methamphetamine in this way is also linked to the trafficking of 
methamphetamine tablets (yaba) to the European Union from 
Southeast Asia to meet the limited demand among specific 
diaspora communities in the European Union originating 
from this region or to the distribution of the drug purchased 
on online marketplaces. More recently, small quantities of 
methamphetamine shipped mainly from the Netherlands by 
postal services have been seized in Austria (Groupe Pompidou, 
2019). This may be related to online supply, such as via the 
darknet for demand in Austria, or in transit to other nearby 
consumer markets, for example in Czechia.
Online trade in methamphetamine
Like many other illicit drugs, methamphetamine is available 
on darknet markets. In the European Union, the share of 
methamphetamine traded between EU-based vendors and 
clients is small compared to other illicit drugs available. 
However, methamphetamine both in its racemic and crystalline 
d-form is available on these marketplaces.
The global nature of the larger darknet marketplaces also 
allows EU consumers to obtain methamphetamine from 
suppliers based outside the European Union. There have been 
isolated cases of intercepted methamphetamine shipments 
trafficked using post and parcel services from production zones 
outside the European Union, e.g. Mexico, to destinations in the 
European Union. However, EU law enforcement authorities 
have repeatedly seized methamphetamine trafficked using 
post and parcel services transiting the European Union 
intended for destinations in Asia. The source regions for 
methamphetamine trafficked via the European Union include 
Central America, Mexico and Africa. 
An analysis of drug advertisements on the darknet from 
January 2015 to August 2019 found that from the 283 000 
listings identified, only 4 000 were for methamphetamine 
shipping from Europe. Most of the methamphetamine sold on 
the darknet in Europe is apparently shipped from Germany 
(38 %), the Netherlands (27 %) and the United Kingdom (13 %), 
and only a small proportion from Czechia (1 %).
In August 2019, a total of 181 active advertisements for 
methamphetamine shipping from Europe were found on 
Berlusconi (125), Empire (49) and Tochka (7) markets. By 
comparison, there were 1 922 listings for cocaine, 1 770 
listings for MDMA and 961 listings for amphetamine during the 
same month. This indicates that methamphetamine is much 
less traded on the darknet than the other common stimulants 
found on the European drug market, reflecting the situation 
prevailing on offline markets and consumer preferences. 
I Organised crime groups
As has been highlighted throughout the report, various types 
of OCGs are involved in the production and distribution of 
methamphetamine in the European Union. This section draws 
together the information to provide an overview of OCG 
involvement. There is some information on the OCGs involved 
in the trafficking of methamphetamine via Europe and the role 
of some OCGs in the intra-EU trafficking of methamphetamine. 
However, there is no clear picture of the extent of 
organised crime involvement in the low-level distribution 
of methamphetamine in Member States with significant 
methamphetamine seizures. Some low-level distribution 
and production activities associated with the ‘ant-smuggling’ 
(little and often) method and small-scale production in 
kitchen-type laboratories appear to be organised primarily by 
methamphetamine consumers to supply small circles of users 
rather than by OCGs. 
The large-scale production of methamphetamine is linked to 
organised crime networks featuring sophisticated structures 
for the acquisition of precursor substances, access to other 
chemicals and custom-made equipment and the distribution 
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of the final product. Small-scale production in Bulgaria is also 
linked to organised crime groups. 
I Dutch OCGs
Dutch OCGs are well-known for their abilities to produce 
significant amounts of MDMA and amphetamine, however, 
they have access to resources and expertise to also 
engage in the large-scale production of methamphetamine. 
Methamphetamine produced by Dutch OCGs is mainly 
intended for export to Australia, Japan and New Zealand, 
although some is also exported to other EU countries. The 
extent to which Dutch OCGs cooperate with Mexican OCGs 
is not currently well understood, although their collusion is 
becoming increasingly apparent.
I Vietnamese OCGs
In addition to their prominent role in the production 
of methamphetamine in Czechia, Vietnamese OCGs 
are also involved in the trafficking and distribution of 
methamphetamine in several other EU countries as well 
as in a range of other criminal activities including cannabis 
production, the facilitation of illegal immigration and trafficking 
in human beings. These trafficking activities often rely on 
links between Vietnamese groups in the main countries of 
production and contacts among the Vietnamese diaspora 
communities in destination countries. In addition, Vietnamese 
OCGs in Czechia also use these contacts to procure 
medicines containing pseudoephedrine in other Member 
States for the production of methamphetamine. Associates 
of Vietnamese OCGs buy medicines containing ephedrine or 
pseudoephedrine in multiple pharmacies in countries where 
the production of methamphetamine typically does not take 
place. They then traffic these pharmaceuticals back to Czechia. 
It is suspected that some Vietnamese groups may exploit legal 
business structures, such as pharmacies, to obtain medicines 
containing ephedrine or pseudoephedrine and divert them for 
the production of methamphetamine.
Vietnamese OCGs have further increased their share of the 
methamphetamine production carried out in Czechia and 
they have also gradually increased their activities in Member 
States bordering Czechia over the last 3 years. They are 
increasingly involved in the production of methamphetamine 
in Slovakia and Poland and are more frequently involved in the 
trafficking and distribution of methamphetamine in Austria and 
Germany. Some links have also been discovered between the 
Vietnamese OCGs based in Czechia and methamphetamine 
production in the Netherlands. 
I Nigerian OCGs
Nigerian OCGs are probably among the most prolific groups 
involved in the international trafficking of methamphetamine 
at global level. They smuggle methamphetamine to various 
markets including Japan and Australia. These countries are 
significant consumer markets for methamphetamine and have 
also been targeted by couriers originating from or travelling via 
Europe in the past. Over the past years, Europol has repeatedly 
noted an increase in the number of methamphetamine 
couriers originating from the European Union arrested in 
destination markets, particularly Japan. It is thought that these 
trafficking activities are primarily orchestrated by Nigerian 
OCGs, which have established global distribution networks for 
the trafficking of methamphetamine produced in West Africa 
(reporting to Europol). Nigerian groups rely on the use of non-
Nigerian couriers in order to avoid border control checks based 
on risk profiles. 
I Mexican OCGs
Mexican groups maintain large-scale laboratories and 
produce significant amounts of methamphetamine for the 
consumer market in the United States. They have substantial 
resources, knowledge and access to drug precursors trafficked 
to Mexico from countries outside the Americas. EU Member 
States have previously intercepted large shipments of drug 
precursors transiting the European Union and destined for 
Mexico. Over the past years, Mexican OCGs have shifted 
some of their methamphetamine production to other Central 
American countries such as Guatemala and Honduras. The 
ability to purchase methamphetamine directly from Mexico 
may increase the trafficking flow of methamphetamine in the 
direction of Europe, although this remains to be seen. The 
involvement of some Mexican nationals in methamphetamine 
production facilities dismantled in the Netherlands and 
Belgium in 2019 may be a sign that Mexican OCGs have 
started producing the drug in Europe, potentially for sale on the 
European market. However, while it seems likely that there is 
some degree of collusion between Mexican and Dutch OCGs, 
the information available at the time of writing does not make it 
possible to either confirm or deny that this is the case. 
I Outlaw motorcycle gangs
Outlaw motorcycle gangs (OMCGs) maintain chapters across 
Europe and are involved in polydrug trafficking especially in 
the Nordic countries. It is likely that OMCGs are involved in the 
distribution of methamphetamine alongside other synthetic 
drugs in the Nordic countries. While Nordic OMCGs have not 
been linked to intra-European methamphetamine trafficking, 
they may procure methamphetamine from OCGs involved in 
trafficking and then distribute the drugs in their domestic markets.
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I Conclusion
Based on the findings presented here, it can be concluded 
that, after a period of relative stability, the threat posed to 
Europe from methamphetamine appears to be increasing. 
While slow and limited diffusion to neighbouring countries 
from the historic producing-region of Czechia is continuing, a 
number of new developments could rapidly become a cause 
for concern. Methamphetamine is increasingly present in 
the Nordic countries, particularly Norway where it is present 
on the amphetamine market. There have been some notable 
developments that are worthy of continued attention, such as 
those related to the availability of drug precursors and new 
alternative chemicals for the production of methamphetamine, 
the criminal groups involved in production and trafficking 
and the relatively recent innovation of supply via darknet 
markets. Europe’s role in the supply of methamphetamine to 
countries outside the European Union relates mainly to the 
supply of large quantities to lucrative markets by synthetic 
drug-producing OCGs situated in or around the Netherlands. 
The involvement of Mexican nationals in methamphetamine 
production in the Netherlands and Belgium is particularly 
concerning.
Distinct patterns of methamphetamine use and different user 
populations are emerging in several regions of Europe, ranging 
from socially integrated users who snort or swallow the drug to 
marginalised users who inject or smoke methamphetamine. 
The exchange of information and monitoring of 
methamphetamine markets in the European Union therefore 
remains an important activity. The analysis of drug residues in 
samples of municipal wastewater is a promising technique for 
monitoring the spread of methamphetamine use in Europe in a 
timely manner. In areas where methamphetamine is present in 
the drug market, law enforcement agencies are encouraged to 
continue to maintain an operational focus on it in order to limit 
its further spread.   
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